You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

1820 Results
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Palliative
Oct 2023
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Oct 2023
Regimen
Intent: Palliative
Oct 2022
Regimen
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
Dec 2023
Regimen
Cancer Type:
Gynecologic, 
Vulva
Intent: Palliative
Oct 2022
Regimen
Cancer Type:
Central Nervous System
Intent: Adjuvant
Funding:
ODB - General Benefit
    temozolomide
Jun 2021
Regimen
Cancer Type:
Breast, 
Gynecologic, 
Endometrial
Intent: Palliative
Funding:
ODB - General Benefit
    exemestane
Nov 2020
Regimen
Cancer Type:
Central Nervous System
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    temozolomide
Jun 2021
Regimen
Intent: Palliative, Curative
Funding:
New Drug Funding Program
    Aldesleukin (interleukin-2) - In-Transit Metastases from Melanoma
May 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Jun 2017
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
ODB - General Benefit
    methotrexate - oral tablets
May 2019
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
Jun 2020

Pages